Across TCGA pan-cancer cohorts, GREB1L Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated GREB1L data layer compared with 24 for mass-spec protein.
The strongest signal is observed in kidney chromophobe (KICH), where higher GREB1L Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GREB1L expression acts as an unfavorable survival marker.
KICH and ESCA are the cancer types where GREB1L Mutation most reproducibly stratifies survival.